MDM2 and acute myeloid leukemia: Fluorescent lanthanide oxyfluoride nanoparticles conjugated with anti-CD-33 antibody for potential treatment of acute myeloid leukemia by conjugating PMI, a dodecameric peptide antagonist of MDM2 and MDMX and a CD-33-targeted humanized monoclonal antibody to nanoparticles via metal thiolate bonds.